Given that PTEN can be a major inhibitor of insulin/IGF signaling [99,100] and is a known target of miR-25 in prostate cancer cells [101], miR-25 may target PTEN to increase insulin/IGF signaling and repress FoxO activity. The gene discussed is IGF1; the disease is prostate carcinoma.